Named on 17 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2019-06-26 to 2026-11-17
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series B contradicted | $120M | 2026-11-17 | [ PART ] |
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series A Verified against 4 of 15 sources | $173M | 2026-11-17 | [ PART ] |
Neurosterix A clinical-stage biotechnology company focused on transforming neuropsychiatric care through selective allosteric modulation | Series B Verified against 1 of 27 sources | $105M | 2026-11-11 | [ LEAD ] |
Anaheim Bio Anaheim Bio is unlocking the power of small molecules to transform disease and improve patients' lives. | Series A Verified against 1 of 17 sources | $44.9M | 2026-11-05 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series F Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $275M | 2026-09-09 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
Kailera Therapeutics Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | ~ 2025-04 | [ PART ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-01-14 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
Oricell Oricell develops cell therapies specifically aimed at treating cancer patients, particularly through advanced CAR-T technology. | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $45M | 2023-02-28 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $210M | 2021-06-15 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2020-07-22 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $104M | 2019-06-26 | [ PART ] |